Epidemiology, Pathology and Histochemistry Features in Women with Breast Cancer

Ali Shahriari Ahmadi¹, Leila Mahdipour¹, Mehrdad Payandeh² and Masoud Sadeghi^3,

¹Rasool-Akram Hospital, Oncology and Hematology ward, Iran University of Medical Sciences, Tehran, Iran

²Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Ali Shahriari Ahmadi, Leila Mahdipour, Mehrdad Payandeh and Masoud Sadeghi. Epidemiology, Pathology and Histochemistry Features in Women with Breast Cancer. American Journal of Cancer Prevention. 2015; 3(3):54-57. doi: 10.12691/ajcp-3-3-2

Abstract

Background: Breast cancer is the most frequent malignancy among women and is the leading cause of death through middle-aged women. Despite the high frequency of breast cancer among Iranian women, the epidemiological characteristics of breast cancer among Iranian patients are yet unknown. Herein, we investigate epidemiology, pathology and histochemistry features in women with breast cancer in Iran. Materials and Methods: Between of 2002 to 2012, 546 patients with breast cancer, who were referred to Rasool-Akram Hospital, Tehran, Iran were studied. They were surveyed for age, size of tumor, family history of disease, laterality, type of pathology, grade, stage, tumor markers and metastasis. Results: The mean age of patients at diagnosis was 46.8±11 years. Size of tumor in 113 patients (20.7%) was 0.1-2 cm, 349 patients (63.9%) between 2.1-5 cm and 84 patients (15.4%) >5 cm. Forty-seven patients (8.6%), 382 patients (70%) and 117 patients (21.4%) had grade I, grade II and grade III, respectively. 185 patients (33.9%) had metastasis (35 patients at diagnosis and 150 patients in time of treatment) to other organs. 538 patients (98.5%) didn’t have family history of ovarian cancer and also 501 patients (91.8%) didn’t have family history of breast cancer. Conclusions: The mean age at diagnosis of BC in Iran is around 46 to 49 years. Tumor size in our study is lower than many studies. The organ as site of the most metastases was the lung in our patients, while in other studies it is the bone.

Keywords:
breast cancer epidemiology pathology

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Payandeh M, Sadeghi E, Sadeghi M, Eskandar AM. Different Presentation of Treatment in Carcinomatous Meningitis of Breast Cancer: Report of 3 Cases. American Journal of Cancer Prevention, 3 (1), 4-7, 2015.
[2]	Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, etals.Breast cancer in Iran: an epidemiological review, Breast J, 13 (4), 383-91, 2007.
[3]	Afsharfard A, Mozaffar M, Orang E, Tahmasbpour E. Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev, 14 (11), 6905-11, 2013.
[4]	Payandeh M, Sadeghi M, Sadeghi E, koohian AK. Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran, American Journal of Cancer Prevention, 2 (2), 37-41, 2014.
[5]	Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer, 5 (8), 591-602, 2005.
[6]	Payandeh M, Khodarahmi R, Sadeghi M, Sadeghi E. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature, Iran J Cancer Prev, 8 (2), 125-8, 2015.
[7]	Chahine G, El Rassy E, Khazzaka A, Saleh K, Rassy N, Khalife N, et al. Characteristics of incident female breast cancer in Lebanon, 1990-2013: Descriptive study of 612 cases from a hospital tumor registry, CancerEpidemiol, 2015.
[8]	Hashemzadeh S, AligholipourMaleki R, Golzari SE. The incidence of breast cancer in northwest iran (2003-2008), J Cardiovasc Thorac Res, 4 (1), 5-9, 2012.
[9]	Yavari P, Pourhoseingholi MA. Socioeconomic factors association with knowledge and practice of breast self-examination among Iranian women, Asian Pac J Cancer Prev, 8 (4), 618-22, 2007.
[10]	Ebrahimi M, Vahdaninia M, Montazeri A.Risk factors for breast cancer in Iran: a case-control study. Breast Cancer Res. 2002; 4 (5): R10.
[11]	Hosseinzadeh M, EivaziZiaei J, Mahdavi N, Aghajari P, Vahidi M, Fateh A, et al.Risk factors for breast cancer in Iranian women: a hospital-based case-control study in tabriz, iran, J Breast Cancer, 17 (3), 236-43, 2014.
[12]	Mahmood H, Faheem M, Mahmood S, Sadiq M, Irfan J.Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan, Asian Pac J Cancer Prev, 16 (3), 1019-24, 2015.
[13]	Ahmad Z, Khurshid A, Qureshi A, Idress R, Asghar N, Kayani N.Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens, Indian J Pathol Microbiol, 52 (4), 477-81, 2009.
[14]	Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results, Breast J, 12 (2), 159-64, 2006.
[15]	Wong HS, Subramaniam S, Alias Z, Taib NA, Ho GF, Ng CH, et al. The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer, Medicine (Baltimore), 94 (8), e593, 2015.
[16]	Laudico A, Redaniel MT, Mirasol-Lumague MR, Mapua CA, Uy GB, Pukkala E, et al. Epidemiology and clinicopathology of breast cancer in metro Manila and Rizal Province, Philippines, Asian Pac J Cancer Prev, 10 (1), 167-72, 2009.
[17]	Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al.Metastatic behavior of breast cancer subtypes, J Clin Oncol, 28 (20), 3271-7, 2010.
[18]	Patanaphan V, Salazar OM, Risco R.Breast cancer: metastatic patterns and their prognosis, South Med J, 81 (9), 1109-12, 1988.
[19]	Berman AT, Thukral AD, Hwang WT, Solin LJ, Vapiwala N. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment, Clin Breast Cancer, 13 (2), 88-94, 2013.
[20]	Nelson HD, Huffman LH, Fu R, Harris EL. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force, Ann. Intern. Med, 143, 362-379, 2005.
[21]	Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer, Breast Cancer Res Treat, 28 (2), 115-20, 1993.